Parkinson Disease in Long Term Care Facilities: A Review of the Literature

Weerkamp, Nico J.; Tissingh, Gerrit; Poels, P.J.E.; Zuidema, Syste U.; Munneke, Marten; Koopmans, Raymond T.C.M.; Bloem, Bastiaan R.

doi:10.1016/j.jamda.2013.10.007

Cited by 33 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 To improve quality of care in these institutions, and to help reduce costs, ParkinsonNet has recently begun a program to also include nursing home care. 10 Health care professionals exhibit high overall satisfaction with ParkinsonNet. Accompanying this satisfaction is greater Parkinson diseasespecific knowledge and a steady increase in patient volume among individual therapists.…”

Section: Parkinsonnetmentioning

confidence: 99%

ParkinsonNet: A Low-Cost Health Care Innovation With A Systems Approach From The Netherlands

et al. 2017

Self Cite

View full text Add to dashboard Cite

ParkinsonNet, a low-cost innovation to optimize care for patients with Parkinson disease, was developed in 2004 as a network of physical therapists in several regions in the Netherlands. Since that time, the network has achieved full national reach, with 70 regional networks and around 3,000 specifically trained professionals from 12 disciplines. Key elements include the empowerment of professionals who are highly trained and specialized in Parkinson disease, the empowerment of patients by education and consultation, and the empowerment of integrated multidisciplinary teams to better address and manage the disease. Studies have found that the ParkinsonNet approach leads to outcomes that are at least as good as, if not better than, outcomes from usual care. One study found a 50 percent reduction in hip fractures and fewer inpatient admissions. Other studies suggest that ParkinsonNet leads to modest but important cost savings (at least US$439 per patient annually). These cost savings outweigh the costs of building and maintaining the network. Because of ParkinsonNet's success, the program has now spread to several other countries and serves as a model of a successful and scalable frugal innovation.

show abstract

Section: Parkinsonnetmentioning

confidence: 99%

ParkinsonNet: A Low-Cost Health Care Innovation With A Systems Approach From The Netherlands

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 The prevalence of PD is estimated to be 0.3% and 1% in general population and older adults aged over 65 years, respectively. 2,3 PD primarily affects voluntary movements; however, lack of dopamine leads to neurobehavioral symptoms and other non-motor features. 1 Both motor and non-motor symptoms contribute to impaired quality of life of patients with PD.…”

Section: Introductionmentioning

confidence: 99%

“…12,13 The efficacy of antipsychotics in patients with dopaminergic psychosis has been evaluated in small clinical trials. 2,14 These clinical trials provided convincing evidence that clozapine is effective in the treatment of PD psychosis, while there are mixed findings regarding the efficacy of other atypical antipsychotics. 2,14 Additionally, cholinesterase inhibitors can improve psychotic symptoms in PD patients, according to a clinical study of cholinesterase inhibitors.…”

Section: Introductionmentioning

confidence: 99%

“…2,14 These clinical trials provided convincing evidence that clozapine is effective in the treatment of PD psychosis, while there are mixed findings regarding the efficacy of other atypical antipsychotics. 2,14 Additionally, cholinesterase inhibitors can improve psychotic symptoms in PD patients, according to a clinical study of cholinesterase inhibitors. 11 Clozapine is not commonly used in clinical practice due to the risk of adverse events such as agranulocytosis and sedation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression</p>

Chekani¹,

Holmes

Johnson³

et al. 2020

DHPS

View full text Add to dashboard Cite

According to the 2015 American Geriatrics Society (AGS) Beers criteria, most antipsychotics are inappropriate in Parkinson's disease (PD) patients due to the risk of worsening Parkinsonian symptoms. This study examined the incidence and predictors of inappropriate antipsychotic use among long-term care residents with PD and comorbid depression. Patients and Methods: This retrospective cohort study utilized 2007-2009 Minimum Data Set (MDS) linked to Chronic Condition Warehouse (CCW) Medicare data files involving patients with PD and comorbid depression. Using a 12-month baseline and a 24-month follow-up, the study examined incidence of inappropriate atypical antipsychotics, namely asenapine, brexpiprazole, iloperidone, lurasidone, olanzapine, paliperidone, risperidone, or ziprasidone as specified in the 2015 AGS Beers criteria. Appropriate atypical antipsychotic included aripiprazole, clozapine, or quetiapine. Multivariable logistic regression was used to examine various sociodemographic and clinical factors associated with inappropriate antipsychotic use in PD based on the Andersen Behavioral Model. Results: The incidence of atypical antipsychotic use was 17.50% (13,352/76,294) among PD patients over a 2-year follow-up. The percentage of inappropriate use among atypical antipsychotic users was 36.32%. The likelihood of inappropriate antipsychotic use was higher for patients who had dementia (OR=1.

show abstract

“…10,11 Institutionalised PD patients have greater mortality when compared to age- and disease duration-matched community-dwelling patients. 12,13 Institutionalisation also distances patients from neurologic expertise, and causes complex loss and grief for the caregiver. 14,15 It is for all of these reasons that interventions to delay or prevent institutionalisation are desperately needed.…”

mentioning

confidence: 99%

Reaching Those Most in Need – A Call to Action for Advanced Parkinson’s Disease

Agarwal

Fleisher

2016

European Neurological Review

View full text Add to dashboard Cite

Much of the clinical and research attention for Parkinson's Disease (PD) has focused on mild to moderate stages. As the disease advances, it can become difficult for patients to attend clinical visits. These patients are often lost to follow-up, and consequently, vanish from the pool of potential research subjects who could inform our management of this understudied population. We aim to increase awareness about this population and potential interventions to improve continuity of care and foster research in advanced PD.

show abstract

Parkinson Disease in Long Term Care Facilities: A Review of the Literature

Cited by 33 publications

References 43 publications

ParkinsonNet: A Low-Cost Health Care Innovation With A Systems Approach From The Netherlands

ParkinsonNet: A Low-Cost Health Care Innovation With A Systems Approach From The Netherlands

<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression</p>

Reaching Those Most in Need – A Call to Action for Advanced Parkinson’s Disease

Contact Info

Product

Resources

About